F-18 FDG-PET imaging and correlation with CT in staging and follow-up of pediatric lymphomas

Pediatric Radiology

Volumn 36, Issue 6, 2006, Pages 524-531

  Hernandez Pampaloni, Miguel ^a   Takalkar, Amol ^b   Yu, Jian Q ^b   Zhuang, Hongming ^b   Alavi, Abass ^b  

^a CHILDREN S HOSPITAL OF PHILADELPHIA   (United States)

^b HOSPITAL OF THE UNIVERSITY OF PENNSYLVANIA   (United States)

Author keywords

Conventional imaging; F 18 FDG PET; Lymphoma; Pediatrics

Indexed keywords

ANTINEOPLASTIC AGENT; FLUORODEOXYGLUCOSE F 18;

ADOLESCENT; ADULT; ARTICLE; CANCER CLASSIFICATION; CANCER STAGING; CHILD; CHILDHOOD CANCER; CLINICAL ARTICLE; COMPUTER ASSISTED TOMOGRAPHY; CONTROLLED STUDY; CORRELATION ANALYSIS; DIAGNOSTIC ACCURACY; DIAGNOSTIC IMAGING; DIAGNOSTIC VALUE; FALSE NEGATIVE RESULT; FALSE POSITIVE RESULT; FEMALE; FOLLOW UP; HISTOPATHOLOGY; HODGKIN DISEASE; HUMAN; HUMAN TISSUE; IMAGE ANALYSIS; INTERMETHOD COMPARISON; MALE; NONHODGKIN LYMPHOMA; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; RETROSPECTIVE STUDY; SENSITIVITY AND SPECIFICITY; STATISTICAL ANALYSIS; STATISTICAL SIGNIFICANCE; TUMOR LOCALIZATION;

ADOLESCENT; ADULT; BIOPSY; CHILD; CHILD, PRESCHOOL; FEMALE; FLUORODEOXYGLUCOSE F18; FOLLOW-UP STUDIES; HODGKIN DISEASE; HUMANS; LYMPH NODES; LYMPHOMA, NON-HODGKIN; MALE; NEOPLASM STAGING; POSITRON-EMISSION TOMOGRAPHY; PREDICTIVE VALUE OF TESTS; RADIOPHARMACEUTICALS; RETROSPECTIVE STUDIES; SENSITIVITY AND SPECIFICITY; TOMOGRAPHY, X-RAY COMPUTED; WHOLE BODY IMAGING;

EID: 33646725676     PISSN: 03010449     EISSN: 14321998     Source Type: Journal    
DOI: 10.1007/s00247-006-0152-z     Document Type: Article

References (29)

1. Magnani C, Gatta G, Coriazzari I, et al (2001) Childhood malignancies in the EUROCARE study: The database and the methods of survival analysis. Eur J Cancer 37:678-686
2. Hudson MM, Donaldson SS (1997) Hodgkin's disease. Pediatr Clin North Am 44:891-906
3. Sandlund JT, Downing JR, Crist WM (1996) Non-Hodgkin's lymphoma in childhood. N Engl J Med 334:1238-1248
4. Edwards BK, Brown ML, Wingo PA, et al (2005) Annual report to the nation on the status of cancer, 1975-2002, featuring population-based trends in cancer treatment. J Natl Cancer Inst 97:1407-1427
5. Brousse N, Vasiliu V, Michon J (2004) Pediatric non-Hodgkin lymphomas. Ann Pathol 24:574-586
6. Thomson AB, Wallace WH (2002) Treatment of paediatric Hodgkin's disease: a balance of risks. Eur J Cancer 38:468-477
7. Pinkerton CR (1999) The continuing challenge of treatment for non-Hodgkin's lymphoma in children. Br J Haematol 107:220-234
8. Reske SN (2003) PET and restaging of malignant lymphoma including residual masses and relapse. Eur J Nucl Med Mol Imaging 30:S89-S96
9. Schiepers C, Filmont FE, Czernin J (2003) PET for staging of Hodgkin's disease and non-Hodgkin's lymphoma. Eur J Nucl Med Mol Imaging 30:S82-S88
10. Schoder H, Larson SM, Yeung HW (2004) PET/CT in oncology: Integration into clinical management of lymphoma, melanoma, and gastrointestinal malignancies. J Nucl Med 45:72S-81S
11. Kumar R, Xiu Y, Potenta S, et al (2004) 18F-FDG PET for evaluation of the treatment response in patients with gastrointestinal tract lymphomas. J Nucl Med 45:1796-1803
12. Elstrom R, Guan L, Baker G, et al (2003) Utility of FDG-PET scanning in lymphoma by WHO classification. Blood 101:3875-3876
13. Depas G, De Barsy C, Jerusalem G, et al (2005) 18F-FDG PET in children with lymphomas. Eur J Nucl Med Mol Imaging 32:31-38
14. Hermann S, Wormanns D, Pixberg M, et al (2005) Staging in childhood lymphoma: Differences between FDG-PET and CT. Nuklearmedizin 44:1-7
15. Munker R, Glass J, Griffeth LK, et al (2004) Contribution of PET imaging to the initial staging and prognosis of patients with Hodgkin's disease. Ann Oncol 15:1699-1704
16. Zinzani PL, Fanti S, Battista G, et al (2004) Predictive role of positron emission tomography (PET) in the outcome of lymphoma patients. Br J Cancer 91:850-854
17. Brenot-Rossi I, Bouabdallah R, Di Stefano D, et al (2001) Hodgkin's disease: Prognostic role of gallium scintigraphy after chemotherapy. Eur J Nucl Med 28:1482-1488
18. Front D, Bar-Shalom R, Mor M, et al (2000) Aggressive non-Hodgkin lymphoma: Early prediction of outcome with 67Ga scintigraphy. Radiology 214:253-257
19. Rini JN, Nunez R, Nichols R, et al (2005) Coincidence-detection FDG-PET versus gallium in children and young adults with newly diagnosed Hodgkin's disease. Pediatr Radiol 35:169-178
20. Kaste SC, Howard SC, McCarville EB, et al (2005) 18F-FDG-avid sites mimicking active disease in pediatric Hodgkin's. Pediatr Radiol 35:141-154
21. Weinblatt ME, Zanzi I, Belakhlef A, et al (1997) False-positive FDG-PET imaging of the thymus of a child with Hodgkin's disease. J Nucl Med 38:888-890
22. Bangerter M, Moog F, Buchmann I, et al (1998) Whole-body 2-[18F]-fluoro-2-deoxy-D-glucose positron emission tomography (FDG-PET) for accurate staging of Hodgkin's disease. Ann Oncol 9:1117-1122
23. Wickmann L, Luders H, Dorffel W (2003) 18-FDG-PET-findings in children and adolescents with Hodgkin's disease: Retrospective evaluation of the correlation to other imaging procedures in initial staging and to the predictive value of follow-up examinations. Klin Padiatr 215:146-150
24. Pinkerton R (2005) Continuing challenges in childhood non-Hodgkin's lymphoma. Br J Haematol 130:480-488
25. Weihrauch MR, Re D, Scheidhauer K, et al (2001) Thoracic positron emission tomography using 18F-fluorodeoxyglucose for the evaluation of residual mediastinal Hodgkin disease. Blood 98:2930-2934
26. Montravers F, McNamara D, Landman-Parker J, et al (2002) [(18)F]FDG in childhood lymphoma: Clinical utility and impact on management. Eur J Nucl Med Mol Imaging 29:1155-1165
27. Kostakoglu L, Goldsmith SJ (2000) Fluorine-18 fluorodeoxyglucose positron emission tomography in the staging and follow-up of lymphoma: is it time to shift gears? Eur J Nucl Med 27:1564-1578
28. Moog F, Bangerter M, Diederichs CG, et al (1998) Extranodal malignant lymphoma: Detection with FDG PET versus CT. Radiology 206:475-481
29. Spaepen K, Stroobants S, Dupont P, et al (2001) Can positron emission tomography with [(18)F]-fluorodeoxyglucose after first-line treatment distinguish Hodgkin's disease patients who need additional therapy from others in whom additional therapy would mean avoidable toxicity? Br J Haematol 115:272-278